免疫原性
医学
接种疫苗
病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
疫苗效力
不利影响
病毒载体
2019年冠状病毒病(COVID-19)
免疫学
疾病
生物
免疫系统
药理学
传染病(医学专业)
重组DNA
病理
基因
生物化学
作者
Cristian Sandoval,Daniela Guerrero,Joham Muñoz,Karina Godoy,Vanessa Souza-Mello,Jorge Farías
标识
DOI:10.1080/14760584.2023.2156861
摘要
Vaccines prevent disease and disability; save lives and represent a good assessment of health interventions. Several systematic reviews on the efficacy and effectiveness of COVID-19 vaccines have been published, but the immunogenicity and safety of these vaccines should also be addressed.This systemic investigation sought to explain the efficacy, immunogenicity, and safety of new vaccination technologies against SARS-CoV-2 in people over 18 years old. Original research studying the effectiveness on mRNA, protein subunit vaccines, and viral vector vaccines against SARS-CoV-2 in people over 18 years old was analyzed. Several databases (Web of Science, Scopus, MEDLINE and EMBASE) were searched between 2012 and November 2022 for English-language papers using text and MeSH terms related to SARS-CoV-2, mechanism, protein subunit vaccine, viral vector, and mRNA. The protocol was registered on PROSPERO, CRD42022341952. Study quality was assessed using the NICE methodology. We looked at a total of six original articles. All studies gathered and presented quantitative data.Our results suggest that new vaccinations could have more than 90% efficacy against SARS-CoV-2, regardless of the technology used. Furthermore, adverse reactions go from mild to moderate, and good immunogenicity can be observed for all vaccine types.
科研通智能强力驱动
Strongly Powered by AbleSci AI